Table 1 Baseline characteristics of 294 patients with Candida bloodstream infection in the CHINA-SCAN study, according to CRCBSI and NCRCBSI

Age (years), mean ± SD

69.4 ± 19.1

60.7 ± 20.2

0.028*

Gender, n (%)

0.527

Male

22 (75.9)

181 (68.3)

Female

7 (24.1)

84 (31.7)

Body weight (kg), mean ± SD

58.0 ± 5.2

63.2 ± 11.0

0.037*

Symptoms, n (%)

Fever

27 (93.1)

243 (91.7)

1.000

Shivers

8 (27.6)

83 (31.3)

0.833

Confusion

13 (44.8)

123 (46.4)

1.000

Concomitant disease, n (%)

Type 1 or 2 diabetes

7 (24.1)

59 (22.3)

0.833

Chronic cardiac dysfunction

6 (20.7)

57 (21.5)

0.891

Solid tumor

8 (27.6)

45 (16.9)

0.180

Chronic obstructive pulmonary disease

4 (13.8)

31 (11.7)

0.762

Chronic renal insufficiency

5 (17.2)

27 (10.2)

0.259

Chronic hepatic insufficiency

4 (13.8)

12 (4.5)

0.060

Hematological malignancy

0 (0.0)

3 (1.2)

1.000

Invasive procedures within 2 weeks prior to diagnosis, n (%)

Hemodialysis

2 (6.9)

15 (5.7)

0.259

Invasive mechanical ventilation

24 (82.7)

204 (77.0)

0.666

Total parenteral nutrition

14 (48.3)

115 (43.4)

0.695

Surgery

11 (37.9)

102 (38.5)

1.000

Immunosuppression

2 (6.9)

15 (5.7)

0.679

Illness severity at ICU admission, mean ± SD

APACHE II score

28.5 ± 7.6

27.0 ± 7.1

0.286

SOFA score

10.6 ± 2.9

11.2 ± 3.5

0.330

Illness severity at diagnosis, mean ± SD

APACHE II score

28.2 ± 7.2

27.0 ± 7.0

0.360

SOFA score

9.8 ± 3.3

10.8 ± 3.5

0.147

Immune enhancement therapy, n (%)^a

21 (72.4)

102 (38.5)

<0.001**

Antibiotic use, n (%)

0.963

Monotherapy

8 (32.0)

75 (35.9)

Two-drug combinations

13 (52.0)

98 (46.9)

Three-drug combinations

4 (16.0)

35 (16.7)

Antibiotic use period, mean ± SD

11.4 ± 4.2

10.6 ± 6.5

0.514

Antibiotic therapy >5 days, n (%)

25 (86.2)

209 (78.9)

0.469

Antifungal therapy, n (%)

28 (96.6%)

229 (86.4%)

0.118

Initial antifungal treatment, n (%)

0.977

Fluconazole

11 (39.3%)

84 (36.7%)

Caspofungin

7 (25.0%)

54 (23.6%)

Voriconazole

4 (14.3%)

44 (19.2%)

Micafungin

3 (10.7%)

20 (8.7%)

Itraconazole

3 (10.7%)

18 (7.9%)

Amphotericin B (liposomes or lipid dispersions)

0

5 (2.2%)

Two-drugs combination^b

0

4 (1.7%)

Treatment duration, mean ± SD

19.0 ± 13.3

16.7 ± 13.3

0.338

Antifungal therapy >5 days, n (%)

8 (27.6)

70 (26.4)

1.000

Time between ICU admission and diagnosis of Candida infection (days), median (Q1,Q3)

11.0 (4.0, 26.0)

10.00 (4.0, 21.0)

0.544